Screening for the Need of Palliative Care among Patients with Advanced, Incurable Cancer

Screening for the Need of Palliative Care among Patients with Advanced, Incurable Cancer - ScreeningPALL

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021686

Enrollment

210

Registered

2020-12-17

Start date

2021-08-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00-C80: Malignant neoplasms (excluding malignant hematologic disorders) C00-C97

Interventions

Group 1: All patients in phase 1 and 2: - 0-2 days after admission for inpatients, during treatment for outpatients: · Completion of the questionnaire Distress Thermometer (self-assessment) · Completi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Arm1 patients: - Patients with metastatic or locally advanced, incurable cancer - = 18 years - Consent by patient or authorized representative Arm2 team members: - Team members of the PMD service of the University Hospital Erlangen, Freiburg and Cologne - Consent Arm3 patients: - Oncological patients - Sufficient knowledge of German and cognitive skills to complete a questionnaire - Consent

Exclusion criteria

Exclusion criteria: Arm 1 patients: - Malignant hematological diseases as the main oncological diagnosis

Design outcomes

Primary

Measure	Time frame
Need for specialist palliative care in incurable cancer patients: assessment after palliative medical history by at least one PMD team member and multi-professional case discussion in the PMD team Sensitivity, specificity, and positive and negative predictive value for Patient Reported Outcome Measures (one-time completion of IPOS and distress thermometer questionnaires), disease-related and treatment-related information, and sociodemographic characteristics of patients	—

Measure

Time frame

Need for specialist palliative care in incurable cancer patients: assessment after palliative medical history by at least one PMD team member and multi-professional case discussion in the PMD team Sensitivity, specificity, and positive and negative predictive value for Patient Reported Outcome Measures (one-time completion of IPOS and distress thermometer questionnaires), disease-related and treatment-related information, and sociodemographic characteristics of patients

—

Secondary

Measure	Time frame
- Examination of the interrater agreement of the assessment of palliative care needs between PMD and the treating oncologists - Exploration of treatment objectives, treatment content, and treatment scope for PMD applications within the project Due to the Covid-19 pandemic, general as well as disease- and care-related burdens of the patients must also be considered and recorded in the trial. In addition to the use of the data as moderator variables in the evaluation with regard to the primary project goals, a descriptive specification of the pandemic-related burdens of patients with advanced cancer will also be provided.	—

Measure

Time frame

- Examination of the interrater agreement of the assessment of palliative care needs between PMD and the treating oncologists - Exploration of treatment objectives, treatment content, and treatment scope for PMD applications within the project Due to the Covid-19 pandemic, general as well as disease- and care-related burdens of the patients must also be considered and recorded in the trial. In addition to the use of the data as moderator variables in the evaluation with regard to the primary project goals, a descriptive specification of the pandemic-related burdens of patients with advanced cancer will also be provided.

—

Countries

Germany

Contacts

Public ContactBettina Couné

Universitätsklinikum Freiburg, Klinik für Palliativmedizin

bettina.coune@uniklinik-freiburg.de0761 270-95910

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 11, 2026